AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.
